Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: The regulatory perspective

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Eckstein, Niels ^a   Röper, Lea ^a   Haas, Bodo ^a   Potthast, Henrike ^a   Hermes, Ulrike ^a   Unkrig, Christoph ^a   Naumann Winter, Frauke ^a   Enzmann, Harald ^a  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

Author keywords

Narrow therapeutic index drugs (NTID); Orphan drug status; Tyrosine kinase inhibitors (TKI)

Indexed keywords

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DRUG AND NARCOTIC CONTROL; DRUGS, GENERIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84893645219     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-15     Document Type: Review

References (39)

1. Cancer statistics, 2013. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2013 63 11 30 10.3322/caac.21166 23335087
2. Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. Laurie SA, Goss GD, J Clin Oncol 2013 31 1061 1069 10.1200/JCO.2012.43.4522 23401452
3. ERBB receptors and cancer: the complexity of targeted inhibitors. Hynes NE, Lane HA, Nat Rev Cancer 2005 5 341 354 10.1038/nrc1609 15864276 (Pubitemid 40637826)
4. Cisplatin resistance: preclinical findings and clinical implications. Koberle B, Tomicic MT, Usanova S, Kaina B, Biochim Biophys Acta 1806 2010 172 182
5. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. Eckstein N, Servan K, Girard L, Cai D, Von JG, Jaehde U, Kassack MU, Gazdar AF, Minna JD, Royer HD, J Biol Chem 2008 283 739 750 10.1074/jbc.M706287200 17942395
6. Platinum resistance in breast and ovarian cancer cell lines. Eckstein N, J Exp Clin Cancer Res 2011 30 91 10.1186/1756-9966-30-91 21967738
7. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, et al. Science 2007 318 287 290 10.1126/science.1142946 17872411 (Pubitemid 47574858)
8. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Engelman JA, Luo J, Cantley LC, Nat Rev Genet 2006 7 606 619 16847462 (Pubitemid 44100518)
9. Molecular predictors of response to tyrosine kinase inhibitors in patients with non-small-cell lung cancer. Murray S, Karavasilis V, Bobos M, Razis E, Papadopoulos S, Christodoulou C, Kosmidis P, Fountzilas G, J Exp Clin Cancer Res 2012 31 77 10.1186/1756-9966-31-77 22992338
10. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR. Wang F, Wang S, Wang Z, Duan J, An T, Zhao J, Bai H, Wang J, J Exp Clin Cancer Res 2012 31 65 10.1186/1756-9966-31-65 22901364
11. The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3 K/Akt cell survival pathway. Mattoon DR, Lamothe B, Lax I, Schlessinger J, BMC Biol 2004 2 24 10.1186/1741-7007-2-24 15550174 (Pubitemid 40251684)
12. Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops. Kiyatkin A, Aksamitiene E, Markevich NI, Borisov NM, Hoek JB, Kholodenko BN, J Biol Chem 2006 281 19925 19938 10.1074/jbc.M600482200 16687399 (Pubitemid 44065766)
13. To kill a tumor cell: the potential of proapoptotic receptor agonists. Ashkenazi A, Herbst RS, J Clin Invest 2008 118 1979 1990 10.1172/JCI34359 18523647 (Pubitemid 351872316)
14. European Medicines Agency, Guideline on the Investigation of Bioequivalence London 2010 CPMP/EWP/QWP/1401/98 Rev. 1/ Corr**
15. European medicins agency. http://www.ema.europa.eu/ema/
16. HumanMRIndex. http://mri.medagencies.org/Human/
17. Chronic myeloid leukemia: diagnosis and treatment. Quintas-Cardama A, Cortes JE, Mayo Clin Proc 2006 81 973 988 10.4065/81.7.973 16835977 (Pubitemid 43993489)
18. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra E, Abruzzese E, et al. J Natl Cancer Inst 2011 103 553 561 10.1093/jnci/djr060 21422402
19. Regulation (EC) No 141/2000 of the European Parliament and of the Council on Orphan Medicinal Products. 2013 http://eur-lex.europa.eu/
20. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Golas JM, Lucas J, Etienne C, Golas J, Discafani C, Sridharan L, Boghaert E, Arndt K, Ye F, Boschelli DH, et al. Cancer Res 2005 65 5358 5364 10.1158/0008-5472.CAN-04-2484 15958584 (Pubitemid 40827349)
21. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D, Cancer Chemother Pharmacol 2012 69 221 227 10.1007/s00280-011-1688-7 21691746
22. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib. Birch M, Morgan PE, Handley S, Ho A, Ireland R, Flanagan RJ, Biomed Chromatogr 2013 27 335 342 22886846
23. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Burris HA III, Taylor CW, Jones SF, Koch KM, Versola MJ, Arya N, Fleming RA, Smith DA, Pandite L, Spector N, et al. Clin Cancer Res 2009 15 6702 6708 10.1158/1078-0432.CCR-09-0369 19825948
24. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Giles FJ, Yin OQ, Sallas WM, le Coutre PD, Woodman RC, Ottmann OG, Baccarani M, Kantarjian HM, Eur J Clin Pharmacol 2013 69 813 823 10.1007/s00228-012-1385-4 23052406
25. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, et al. Clin Cancer Res 2012 18 1092 1100 10.1158/1078-0432.CCR-11- 2378 22179664
26. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R, Mol Cancer Ther 2008 7 1185 1194 10.1158/1535-7163.MCT-08-0126 18483306
27. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Demetri GD, Lo RP, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR, Clin Cancer Res 2009 15 6232 6240 10.1158/1078-0432.CCR-09-0224 19789325
28. Erlotinib: a new therapeutic approach for non-small cell lung cancer. Bonomi P, Expert Opin Investig Drugs 2003 12 1395 1401 10.1517/13543784.12.8. 1395 12882624 (Pubitemid 36949696)
29. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, et al. Cancer Res 1997 57 4838 4848 9354447 (Pubitemid 27468992)
30. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH, Cancer Res 2002 62 5749 5754 12384534 (Pubitemid 35204731)
31. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB, Nat Med 1996 2 561 566 10.1038/nm0596-561 8616716 (Pubitemid 26151518)
32. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, et al. Mol Cancer Ther 2001 1 85 94 12467226
33. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Kantarjian H, Le CP, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O, Cancer 2010 116 2665 2672 20310049
34. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Yau T, Chen PJ, Chan P, Curtis CM, Murphy PS, Suttle AB, Gauvin J, Hodge JP, Dar MM, Poon RT, Clin Cancer Res 2011 17 6914 6923 10.1158/1078-0432.CCR-11-0793 21831954
35. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a national cancer institute organ dysfunction working group study. Shibata SI, Chung V, Synold TW, Longmate JA, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton AL, et al. Clin Cancer Res 2013 19 3631 3639 10.1158/1078-0432.CCR-12-3214 23653147
36. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Infante JR, Novello S, Ma WW, Dy GK, Bendell JC, Huff A, Wang Q, Suttle AB, Allen R, Xu CF, et al. Invest New Drugs 2013 31 927 936 10.1007/s10637-012-9900-0 23179337
37. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, Cihon F, Lathia C, Schwartz B, Ann Oncol 2005 16 1688 1694 10.1093/annonc/mdi310 16006586 (Pubitemid 41510145)
38. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. Cancer Res 2004 64 7099 7109 10.1158/0008-5472.CAN-04-1443 15466206 (Pubitemid 39331023)
39. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, et al. J Clin Oncol 2006 24 25 35 10.1200/JCO.2005.02.2194 16314617 (Pubitemid 46630490)